Mechanism of Action
Anti-Glycation Activity
Like carnosine, acetyl tetrapeptide-5 inhibits the Maillard reaction (non-enzymatic protein glycation) in which glucose reacts with lysine and arginine residues on collagen, elastin, and other proteins to form advanced glycation end products (AGEs). AGEs cross-link matrix proteins, reducing their elasticity and increasing opacification of periorbital skin. The histidine imidazole ring and beta-alanine of acetyl tetrapeptide-5 chelate the reactive carbonyl intermediates and scavenge free radicals that drive glycation, protecting matrix proteins from age-related cross-linking damage.
Capillary Stabilization and Edema Reduction
Acetyl tetrapeptide-5 strengthens capillary basement membranes by stabilizing collagen IV and laminin in periorbital microvasculature. Fragile capillaries in the thin periorbital skin are prone to microhemorrhages, releasing hemoglobin that is converted to hemosiderin (dark iron deposits), contributing to dark circles. By reducing vascular permeability and capillary fragility, the peptide decreases microhemorrhage frequency and fluid transudation. This reduces the accumulation of interstitial fluid and blood breakdown products that create the appearance of bags and dark circles.
Lymphatic Drainage Enhancement
Research suggests acetyl tetrapeptide-5 promotes lymphatic vessel function in periorbital tissue by activating VEGFR3 signaling on lymphatic endothelial cells, improving lymph flow and reducing lymphatic stasis. Impaired lymphatic drainage is a major contributor to periorbital edema, especially in the morning when horizontal positioning and reduced lymphatic pumping allow fluid accumulation overnight. Enhanced lymphatic clearance reduces this morning puffiness.
Research Summary
Eye Puffiness Reduction
Clinical (cosmetic)Clinical studies of formulations containing 3-5% Eyeseryl show significant reductions in periorbital edema measured by high-frequency ultrasound (dermis + hypodermis thickness) and visual grading. A Sederma-sponsored study showed 70% of subjects had measurable reductions in under-eye bags after 56 days of use twice daily. Optical profilometry confirms reductions in skin texture irregularities in the periorbital area.
Dark Circle Improvement
Clinical (cosmetic)In clinical studies using colorimetry (L*a*b* values) and visual assessment, acetyl tetrapeptide-5 formulations reduced darkness measured by lower a* (redness from hemoglobin) and b* (yellow/brown from hemosiderin) values under the eyes. The anti-glycation and capillary-strengthening actions address two of the main dark circle mechanisms, though the response varies significantly between dark-circle subtypes (vascular vs. pigmented vs. structural).
Carnosine Analogue Research Context
ResearchCarnosine (beta-Ala-His) has extensive research supporting anti-glycation, antioxidant, and anti-aging effects in various tissues. Acetyl tetrapeptide-5 is positioned as a carnosine analogue with enhanced skin penetration (due to its tetrapeptide length and acetylation) and possibly enhanced anti-glycation potency. The carnosine research base provides mechanistic context, though direct head-to-head studies of acetyl tetrapeptide-5 vs carnosine in skin are limited.
Calculate your Acetyl Tetrapeptide-5 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Periorbital anti-aging treatment | 0.01-0.1% in eye cream formulation | Twice daily morning and evening application | Topical to under-eye area |
| Anti-glycation assay | 1-100 mcM in BSA-glucose glycation model | Incubation at 37 C for 1 week | In vitro assay |
| Capillary permeability study | 10-100 mcM in endothelial culture | Continuous exposure 24-48h | Cell culture medium |
The periorbital area has thinner, more sensitive skin than the rest of the face. Formulations should be tested for ophthalmologic safety (eye irritation testing). Avoid contact with eyes. The very low concentration (0.01%) still provides cosmetic activity.
Interactions
Safety Profile
Acetyl tetrapeptide-5 has an excellent cosmetic safety profile established through HRIPT and ophthalmological safety testing. Non-sensitizing, non-irritating for normal and sensitive skin types. Safe for use near the eyes, ophthalmic safety tests (BCOP, FLET) confirm eye safety at cosmetic concentrations. No systemic absorption concern at topical concentrations. Not tested in pregnancy; general avoidance of novel cosmetic actives during pregnancy commonly recommended. No photosensitization, comedogenicity, or mutagenicity concerns.
References
- [1]Sederma Technical Data. Eyeseryl: acetyl tetrapeptide-5 for periorbital area. Croda International. 2010.
- [2]Lupo MP. Cosmeceutical peptides. Dermatol Ther. 2007;20:343-349.
- [3]Alijotas-Reig J, et al. Carnosine and carnosine-related peptides: pharmacology and biochemical functions in sensory organs and brain. Amino Acids. 2021.